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Abstract
Gemcitabine is an antineoplastic used to treat several 
malignancies including pancreatic cancer. Its toxicity 
profile is well known with myelotoxicity, increased va-
scular permeability and peripheral oedema as most fre-
quent adverse events. However, several cases of acute 
renal failure have been reported and haemolytic uremic 
syndrome (HUS) seems to be the underlying process. The 
cause of HUS remains unknown but its consequences 
can be lethal. Therefore, a high grade of suspicion is cr-
ucial to diagnose it and promptly treat it. This hopefully 
will reduce its morbidity. HUS is characterized by pro-
gressive renal failure associated with microangiopathic 
haemolytic anaemia and thrombocytopenia. The primary 
event is damage to endothelial cells and thrombotic 
microangiopathy (TMA) is the histopathological lesion. 
TMA affects mainly renal microvasculature. However, so-
me cases evolve with central nervous or cardiovascular 
systems involvement. We present here a case of ge-
mcitabine-induced HUS, with renal and cardiovascul-
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ar system affected at the time of diagnosis which to 
our knowledge this is the first time of such case to be 
reported.
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Core tip: Gemcitabine has a well-known toxicity pro-
file though rare cases of acute renal failure caused by 
haemolytic uremic syndrome (HUS) have also been 
reported. The cause of HUS remains unknown but its 
consequences may be lethal. HUS consists of progre-
ssive renal failure with microangiopathic haemolytic 
anaemia and thrombocytopenia. Thrombotic microan-
giopathy is the histopathological lesion and this affects 
mainly renal microvasculature. We present a case of 
gemcitabine-induced HUS and review literature to ma-
ke professionals fully aware of its existence, thus a 
high grade of suspicion might help with early diagnosis 
and prompt treatment which hopefully will reduce its 
morbidity.
Cidon EU, Martinez PA, Hickish T. Gemcitabine-induced 
haemolytic uremic syndrome, although infrequent, can it be 
prevented: A case report and review of literature. World J Clin 
Cases 2018; 6(12): 531-537  Available from: URL: http://www.
wjgnet.com/2307-8960/full/v6/i12/531.htm  DOI: http://dx.doi.
org/10.12998/wjcc.v6.i12.531
INTRODUCTION
Gemcitabine is an antimetabolite drug used in the tr­
eatment of several malignancies including pancreatic 
cancer[1]. Although it has got multiple adverse effects, 
the most relevant ones include myelotoxicity, increa­
sed vascular permeability and peripheral oedema. Un­
fortunately, several cases of acute renal failure have also 
been reported and haemolytic uremic syndrome (HUS) 
appears to be the underlying process. The cause of this 
syndrome and its treatment remain unknown[2] but its 
consequences may be lethal. 
HUS is characterized by progressive renal failure 
associated with microangiopathic haemolytic anaemia 
and thrombocytopenia. The primary event in this sy­
ndrome’s pathology is damage to endothelial cells. Th­
rombotic microangiopathy (TMA) is the key histopath­
ological lesion for which the features are thickening and 
inflammation of the walls of arterioles and capillaries, 
disengagement of endothelial cells, accumulation of 
proteins and cellular debris in the endothelium, and the 
formation of platelet thrombi that obstruct the vessels 
lumen[3]. TMA involves mainly the renal microvascula­
ture but involvement of the central nervous system, 
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cardiovascular system, lungs, skin, skeletal muscle and 
gastrointestinal tract occurs in 20% of patients[4]. 
The most frequent cause of HUS is an infection 
by Escherichia coli which produces Shiga toxin. This is 
known as “typical HUS”[5]. However, other factors can 
also cause HUS, known as “secondary HUS”. Among 
these factors, pregnancy, organ transplantation, other 
infections and medical treatments such as gemcitabine 
can be named[6]. 
The association of HUS with gemcitabine has been 
reported several times in the literature but to our know­
ledge this is the first case with cardiovascular system 
involvement at the time of diagnosis. The incidence of 
this complication seems to be low, but underreporting 
is also a possibility[7]. Although infrequent, HUS is a seri­
ous complication and a high grade of suspicion is needed 
to diagnose it early and initiate treatment. Uncertainty 
exists regarding the best treatment to apply, although 
discontinuation of gemcitabine is agreed as the first step. 
We present here a recent case seen in our Department. 
The patient has survived but unfortunately she remains 
dialysis dependent. 
CASE REPORT
In April 2017, a 66­year­old Caucasian female with 
a history of a deep vein thrombosis after an air flight 
a few years back, was admitted due to extreme fati­
gue, peripheral oedema and general malaise. She had 
been previously diagnosed with an ampullary aden­
ocarcinoma and underwent a Whipple’s procedure (pa­
ncreatico­duodenectomy and splenectomy) in June 
2016. Pathological results showed a pT4pN1 (3/5) R0 
adenocarcinoma. Her postoperative period was a little 
difficult. She complained of restless legs, sleeplessne­
ss, occasional diarrhoea and vomiting not following any 
pattern. She required expert dietician to support. On 
the suspicion of pancreatic insufficiency, her pancrea­
tic enzymes were increased. She was also started on 
Quinine Sulphate to help with restless legs and continued 
to take Omeprazole, Metoclopramide, Zopiclone and 
Erythromycin. 
A few months after her surgery, she was started 
on adjuvant treatment with gemcitabine. Initially she 
had been planned for a combination with capecitabine 
but due to her diarrhoea, this plan was abandoned. 
The dose of gemcitabine was reduced for the first cycle 
in view of her long postoperative period to recover up 
to an acceptable level of fitness to start her adjuvant 
chemotherapy. The plan was to re­evaluate at the se­
cond visit. 
She developed diarrhoea (3 episodes daily) and 
mild fatigue, phlebitis post­cannulation in arms and 
phlebitis in legs which were painful and hard to touch. 
She was then started on Rivaroxaban 10 mg daily and 
recommended to apply topical Hydrocortisone. She de­
clined a PICC line. She also developed one episode of a 
prolonged chest infection without any neutropenia. This 
October 26, 2018|Volume 6|Issue 12|
533WJCC|www.wjgnet.com
was treated with Doxycycline and needed a delay of 
her planned 2nd cycle. 
Due to all these side­effects, we decided to keep 
the dose reduced by 20% as performed for the first 
cycle. After cycle 4, she complained of sore mouth CTC 
(Common Terminology Criteria for Adverse Events used 
by oncologists to classify the intensity of side­effects 
(https://ctep.cancer.gov/protocoldevelopment/electr­
onic_applications/ctc.htm) grade 2 and continued with 
her usual diarrhoea although only CTC grade 1. Her ha­
emoglobin levels had been fluctuating between 123 
g/L and 95 g/L and her creatinine between 69 µmol/L 
and 107 µmol/L. At her pre­chemotherapy appointment 
for cycle 6 (last cycle), she complained of extreme 
fatigue and significant peripheral oedema lasting for 
the previous 2 wk. On the day of the appointment she 
was feeling significantly better and the oedema had 
significantly resolved. Following discussion with the pati­
ent about the risks of having the final cycle vs discon­
tinuation, she proceeded with day 1 and day 15th, but 
to avoid day 8th as she would be on holidays. 
Her haemoglobin was 78 g/L and her creatinine 
levels had increased to 146 µmol/L. At the time these 
were considered to be due to bone marrow toxicity with 
gemcitabine itself and the increased creatinine levels as 
being pre­renal cause, resulting from suboptimal fluid 
intake. 
She went ahead with day 1 and received two units 
of blood with clinical benefit. Two weeks later, before 
day 15th, she presented to the acute medical oncology 
department with a complaint of extreme fatigue and 
weakness, peripheral oedema and feeling generally 
unwell, with mild dizziness and mild chest pain. On 
examination, she was tachycardic with a pulse of 120 
bpm, blood pressure of 202/83 mmHg, respiratory ra­
te of 18 and afebrile. She looked pale, dehydrated and 
with significant peripheral oedemas. She did not have 
any skin rash or purpura. Laboratory workup showed a 
creatinine of 392 µmol/L (baseline of 69 µmol/L), whi­
ch gradually went up to 759 µmol/L in 48 h. Full blood 
count (FBC) showed haemoglobin of 92 g/L, hematoc­
rit of 0.275 L/L, reticulocytosis of 3.2% and a white cell 
count of 22 × 109/L. Her platelet count was 77 × 109/L. 
Troponin was 509 ng/L and the electrocardiogram sh­
owed a NSTEMI with widespread T­wave inversion. 
An echocardiogram showed all apical regions akine­
tic, with an ejection fraction of 45%, moderate diastolic 
impairment and a chest X­ray reported a mild left pleural 
effusion. Urinalysis showed mild proteinuria. The patient 
was intensively managed according to the unit relevant 
protocols. Her lactate dehydrogenase (LDH) level was 
elevated to 2328 iU/L (90­275) and haptoglobin was 
< 0.10 g/L (0.5­2.40). Her ADAMTS­13 levels were 87 
(64­132). Peripheral smear was examined and showed 
anisocytosis, poikilocytosis, microspherocytes, roulea­
ux formation and few platelet clumps. An ultrasound of 
the renal tract demonstrated normal kidneys with non­
obstructing features. A CT scan showed doubts with 
peritoneal metastases. The working diagnosis of HUS 
probably induced by gemcitabine was made as the pa­
tient had not had evidence of malignant recurrence. Her 
cardiology issues were optimised and she was started 
on steroids (high dose prednisolone) and although initia­
lly the patient was very reluctant to other treatments, 
eventually she accepted haemodialysis. She has been 
under close follow up and continues free of recurrence 
eighteen months after this episode. Her echocardiogr­
am has shown improvement with hypokinesis of a single 
mid­septal segment. The remaining wall motion appe­
ars normal with globally preserved ejection fraction (> 
55%) and left ventricular diastolic function is moderately 
impaired. She had received a total cumulative dose of 
23940 mg of gemcitabine before cycle 6 and received 
cycle 6 day 1 as her haemoglobin drop was put in rela­
tion to gemcitabine haematological toxicity as mentioned 
above. The patient now feels clinically well although this 
has impacted negatively on her quality of life as she 
remains dialysis­dependant. 
DISCUSSION
Gemcitabine is an antineoplastic agent commonly used 
in the treatment of several cancers such as pancreatic, 
lung, breast and other tumours. It is an analog of deo­
xycytidine and works as a pro­drug. Once transported 
into the cell, it must be phosphorylated by deoxycytidine 
kinase to change it into the active form that will inhibit 
DNA synthesis[1,8]. Several phase Ⅰ studies of gemcita­
bine as single agent have recommended 1000 mg/m2 
administered as a 30 min infusion[8,9]. 
With this regimen, the toxicity profile is low, with 
myelosuppression as most frequent adverse event[10]. 
Other studies have shown similar efficacy with prolonged 
infusions[11], although some have suggested that it could 
increase cytotoxicity and survival[12]. However, it clearly 
increases the rate of haematological toxicities grade 3­4. 
Therefore, it continues to be administered as a 30 min 
infusion[13] in pancreatic adenocarcinoma. 
Other side­effects include mainly increased vascular 
permeability and peripheral oedema but several cases 
of HUS have been documented as well[2]. It is difficult 
to estimate HUS incidence as it is easily underreported 
but the literature have published 0.078% in clinical tri­
als and 4% when taken from spontaneous sources[14,15]. 
HUS is characterized by renal failure, thrombocytop­
enia and microangiopathic hemolytic anemia (MAHA), 
proteinuria and haematuria. MAHA consists of increas­
ed levels of LDH, low haptoglobin and the presence of 
schistocytes on the peripheral blood smear. Unfortunate­
ly HUS diagnosis is often delayed due to the fact that 
anaemia and thrombocytopenia might be attributed to 
myelotoxicity of the drug itself[16]. However, when these 
toxicities are combined with renal insufficiency, a high 
index of suspicion is needed to prompt a laboratory wor­
kup looking for signs of haemolysis[17]. 
There are other reasons leading to the difficulties 
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in diagnosis. The lack of physicians’ awareness or the 
patients’ poor oral intake, diarrhoeas, older age or co­
morbid diseases such as hypertension, diabetes, or 
vascular disease, may contribute. Glezerman et al[18] 
reviewed 29 patients with gemcitabine nephrotoxicity 
and described new onset or worsening hypertension in 
26; oedema, shortness of breath and congestive heart 
failure in 21, 15 and 7 patients respectively[18]. All of them 
developed anaemia, thrombocytopenia and elevated se­
rum LDH. Haptoglobin was low and schistocytes were 
present in most of them[18]. These authors concluded 
that gemcitabine­induced HUS presents as new­onset 
renal failure with hypertension, thrombocytopenia and 
MAHA, but agree that the final diagnosis is not easy 
and emphasise again the relevance of a high index of 
suspicion[18]. 
In addition to this, there could be patients showing 
only a small decrease in renal function. In these patients, 
an increase in serum creatinine might be the only sign 
of HUS[19]. However, physicians need to know that mild 
renal deterioration resolving quickly on rehydration is 
not related to HUS. To add even more difficulties, some 
patients develop livedo reticularis in lower extremities 
or digital necrosis as an early sign of HUS[20]. We have 
recently published a review of 157 patients on adjuvant 
gemcitabine for pancreatic adenocarcinoma. Two pa­
tients developed gemcitabine­HUS. Both had a drop in 
haemoglobin of 37% and 34% from the baseline levels 
and a drop in creatinine clearance of 41% and 31%. 
Logistic regression analysis showed that a drop in ha­
emoglobin > 25% and in creatinine clearance > 30% 
from baseline, increased significantly the chances of 
ending on hemodyalisis (P = 0.0001)[21]. We proposed 
that in those suspicious cases, gemcitabine should be 
at least delayed to undertake all those extra laboratory 
tests and confirm or dismiss this diagnosis before a final 
decision regarding gemcitabine continuity is made[21]. 
Serke et al[17] recommended reticulocyte­counting 
if patients develop anaemia or thrombocytopenia. If st­
rongly elevated, this supports hyperregenerative anaem­
ia due to haemolysis, ruling out myelotoxicity. Coombs 
test can also be performed and it should be negative if 
renal insufficiency is not related to HUS[22]. Finally, in some 
cases, a renal biopsy could be considered to be able to 
confirm this complication[22]. In the case presented here, 
we established the diagnosis based on clinic­analytical 
parameters and although a renal biopsy was consider­
ed and discussed, this was finally abandoned. To throw 
more challenges to the diagnosis, timing and cumulative 
dose behind HUS are variable[7,14,15,23,24]. Whereas Fung 
at al[15] documented HUS within 1 to 2 mo of the last 
infusion with a median of cumulative dose of 18252 
mg/m2, Flombaum et al[25] reported a broad range of 
cumulative doses, from 2450 to 48000 mg/m2. None of 
these authors found a dose­response relationship[24]. HUS 
may also occur many months after the last infusion[25,26]. 
As such this variability further clouds the its’ recognition 
and so encourages awareness that it is a risk, possibly 
serious of this treatment. Unfortunately its prognosis is 
poor, with mortality rates ranging from 10% to 40% in 
most series[27] to as high as 60%­70% in others[23]. 
Although gemcitabine­induced HUS occurs in early 
and advanced disease, older literature reviews indica­
te that it is more frequent when the patient is free of 
disease or has minimal tumour burden[25]. However, 
HUS could be cancer associated as well but this is more 
frequent with metastatic disease[25,27]. The mechanism 
or mechanisms behind HUS are unknown, but one hy­
pothesis propose a micro vascular endothelial injury 
as the key. This may be via a direct gemcitabine in­
teraction or indirectly following neutrophil or platelet 
activation[28,29]. 
Others are inclined to think that the origin is imm­
unologic, following the observation that there appears 
to be benefit from treatments that remove circulating 
immunocomplexes or from immunosuppressants[30]. 
Reduced complement and partial reduction in the ac­
tivity of ADAMTS13 (< 60% of normal activity) have 
been documented in most patients with atypical HUS, 
respectively. This has led to the proposal that functio­
nal tests of ADAMTS13 should be considered in these 
patients[31]. Consistent with this observation, metastatic 
cancers may have reduced serum ADAMTS13 activity[32]. 
Another mechanism taken into consideration is the ac­
tivation of the clotting pathway following gemcitabine 
drug­induced endothelial injury[33]. 
In addition platelet activation may be a secondary 
response to endothelial injury[34]. In TMA, the renal 
and cerebral vessels are commonly involved, while the 
pulmonary and hepatic microvasculature is usually sp­
ared. Evidence also indicates that acute myocardial 
infarction is an early, frequent and severe complication 
during TMA[35]. A study with 74 patients with TMA (not 
associated with gemcitabine) showed that 18% had 
acute myocardial infarctions, 9 non­ and 5 ST­segment 
elevation. All these episodes happened 5 ± 3 d after 
the TMA diagnosis predominantly in thrombotic thro­
mbocytopenic purpura. This caused left ventricular dys­
function in 3 of 8 survivors[36]. 
Cardiac complications are frequently seen in thr­
ombotic thrombocytopenic purpura and also occur in 
atypical HUS. Therefore these patients should be ass­
essed for cardiac sequelae[36]. Our patient showed signs 
of myocardial infarction in the context of haemolysis 
which we have not seen reported before in gemcitabine­
induced HUS, and this was an early complication. Ano­
ther issue with gemcitabine­induced HUS is the optim­
al management. Immediate discontinuation[19] seems 
appropriate as first step, although it is unknown wheth­
er this ameliorates the course of the syndrome. Other 
interventions include steroids, transfusions, dialysis, 
plasmapheresis, vincristine, rituximab and more recently 
eculizumab[5,29] with limited effectiveness[16,30,31]. Plasma­
pharesis has shown to modify the evolution of haemolytic 
anaemia but not in renal impairment[5,29].
Recent studies have explored the use of Rituximab 
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(an anti­CD20 monoclonal antibody) and Eculizumab. 
Eculizumab is a recombinant humanized monoclonal an­
tibody that binds to complement C5 protein and inhibits 
its cleavage, preventing the generation of the infla­
mmatory peptide C5a and the cytotoxic membrane­attack 
complex C5b[9,37]. The most frequent side­effects are 
headache, anaemia and diarrhea[38]. Neisseria meningitidis 
vaccination is also indicated at least two weeks prior 
to treatment[39]. It has shown a fast and sustained 
interruption of the TMA process in patients with non­
atypical HUS, including those with drug­induced HUS[40] 
and it has been associated with significant long­term 
improvements in renal function, the interruption of 
plasmapheresis and important reductions in the need for 
dialysis[6]. Al Ustwani et al[19] have reported resolution of 
the haemolysis and thrombocytopenia in four patients 
with gemcitabine­induced HUS. Renal function improved 
significantly although it did not return to baseline and 
only one patient required temporary haemodialysis, but 
renal function subsequently improved[19]. Although Eculi­
zumab has been recently approved by FDA for atypical 
HUS, its role in malignancy or chemotherapy induced 
HUS has not been defined[41,42] and its current cost limits 
accessibility[19]. 
Bharthuar et al[43] presented a case of gemcitabine­
induced HUS which was aggressively treated with plas­
mapheresis, high­dose steroids, vincristine and rituxi­
mab. The patient improved clinically and the platelets 
recovered concurrently with administration of rituximab 
but needed aggressive supportive measures to manage 
renal failure (haemodialysis) and hypertension. 
Ritchie et al[44] reported their experience of managing 
three patients with pancreatic adenocarcinoma who 
developed gemcitabine­induced HUS. One patient show­
ed some benefit with plasmapheresis and rituximab re­
sulted in durable resolution of HUS in the others. These 
authors concluded that immune based therapies seem 
to reverse haemolysis and stabilise renal function[44]. 
Although there is an urgent need for better therapy, it 
seems that immunotherapy offers promise but requires 
more evaluation. In the case reported here, we did not 
see any significant benefit with steroids but the patient 
was very reluctant to receive any other treatments. 
She was not keen on trying any other options after 
knowing potential side­effects and the uncertain bene­
fits. Rituximab and Eculizumab were mentioned in the 
discussion but finally abandoned for these reasons. It 
was only after several long discussions with the patient 
and a significant clinical deterioration that she finally 
accepted haemodialysis. We can conclude here that 
gemcitabine­induced HUS is a rare but serious toxicity 
with significant morbidity and mortality that requires 
prompt diagnosis and intervention. We hope that this 
article would help all professionals, making them aware 
of this extremely serious syndrome. Subtle signs such as 
increase level of serum creatinine or a significant drop 
in haemoglobin should flag an alert. Gemcitabine should 
then be withheld to undertake all the required laboratory 
workup to confirm or dismiss this diagnosis. However, 
as previously discussed, it is unknown if this measure 
would be able to stop or minimize the damage already 
initiated. 
ARTICLE HIGHLIGHTS
Case characteristics
A 66-year-old female developed a significant renal impairment and anaemia 
while receiving adjuvant Gemcitabine. 
Clinical diagnosis
She was diagnosed with haemolytic uremic syndrome.
Laboratory diagnosis
Her laboratory tests showed haemolysis and ruled out any myelotoxicity. 
Imaging diagnosis
An electrocardiogram showed a NSTEMI with widespread T-wave inversion. A 
renal US did not show any evidence of lesion or cortical damage. 
Pathological diagnosis
Although considered a renal biopsy, this was finally declined.
Differential diagnosis
Myelotoxicity and general decline with low intake and dehydration but these 
were ruled out immediately after receiving results showing haemolysis. 
Myocardial infarction as the cause but ruled out after parameters showing 
haemolysis, and considered a consequence of the haemolysis as part of the 
thrombotic microangiopathy (TMA). 
Treatment
Steroids were tried and she was also started on aspirin. Haemodialysis was 
needed.
Term explanation 
HUS: Haemolytic uremic syndrome; TMA: Thrombotic microangiopathy.
Experiences and lessons
Subtle signs such as increase level of serum creatinine or a significant drop 
in haemoglobin should flag an alert in patients on Gemcitabine. Although it is 
unknown if by withholding Gemcitabine this would be able to stop or minimize 
the damage already initiated, this should be done until all the laboratory workup 
to confirm or dismiss the diagnosis has been performed and received. 
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